dirkv
32 minutes ago
Sarasota, FL – December 16, 2024 – Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today
announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock. The c